Login / Signup

Antigen priming induces functional reprogramming in iNKT cells via metabolic and epigenetic regulation: An insight into iNKT cell-based anti-tumor immunotherapy.

Huimin ZhangSanwei ChenYuwei ZhangChenxi TianJun PanYu WangShiyu BaiQielan WuMiya SuDi XieSicheng FuShuhang LiJing ZhangYusheng ChenShasha ZhuYeben QianLi Bai
Published in: Cancer immunology research (2023)
Dysfunction of intratumoral invariant natural killer T (iNKT) cells hinders their anti-tumor efficacy, but the underlying mechanisms and the relationship with endogenous antigen priming remain to be explored. Here, we report that antigen priming leads to metabolic reprogramming and epigenetic remodeling, which causes functional reprogramming in iNKT cells, characterized by limited cytokine responses upon restimulation but constitutive high cytotoxicity. Mechanistically, impaired oxidative phosphorylation (OXPHOS) in antigen-primed iNKT cells inhibited TCR signaling, as well as elevation of glycolysis, upon restimulation via reducing mTORC1 activation, and thus led to impaired cytokine production. However, the metabolic reprogramming in antigen-primed iNKT cells was uncoupled with their enhanced cytotoxicity; instead, epigenetic remodeling explained their high expression of granzymes. Notably, intratumoral iNKT cells shared similar metabolic reprogramming and functional reprogramming with antigen-primed iNKT cells due to endogenous antigen priming in tumors, and thus recovery of OXPHOS in intratumoral iNKT cells by ZLN005 successfully enhanced their anti-tumor responses. Our study deciphers the influences of antigen priming-induced metabolic reprogramming and epigenetic remodeling on functionality of intratumoral iNKT cells, and proposes a way to enhance efficacy of iNKT cell-based anti-tumor immunotherapy by targeting cellular metabolism.
Keyphrases
  • induced apoptosis
  • cell cycle arrest
  • gene expression
  • endoplasmic reticulum stress
  • dna methylation
  • signaling pathway
  • cell death
  • single cell
  • immune response
  • pi k akt
  • cell therapy